Log In
Print
BCIQ
Print
Print this Print this
 

EDP-239

  Manage Alerts
Collapse Summary General Information
Company Enanta Pharmaceuticals Inc.
DescriptionHCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today